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Abstract
Background: We conducted a prospective cohort study to investigate prevalence of poststroke cognitive
impairment at 3 and 12 months after stroke onset and identify clinical and demographic factors associated with
improvement or decline in cognitive function between 3 months and 12 months.
Methods: We analyzed the cognitive assessments of total patients and patients older than 65 years separately. All
patients with an ischemic stroke were divided into normal cognitive group (NCG) and impaired cognition group
(ICG) by using a cutoff score on the Korean Mini-Mental State Examination (K-MMSE). Patients were additionally
classified into 3 subgroups according to the changes in their K-MMSE scores between 3 and 12 months: Stable
group with K-MMSE scores changes ranging from −2 to +2 points (−2≤ △MMSE ≤ +2); converter group with
increase more than 3 points (3 ≤ △MMSE); and reverter group with decrease more than 3 points (−3 ≤ △MMSE). We
also analyzed factors affecting cognitive change from 3 months to 12 months among the 3 groups including
baseline medical record, stroke and treatment characteristics, and various functional assessments after 3 months.
Results: This study included 2,625 patients with the first time ischemic stroke. Among these patients, 1,735 (66.1%)
were classified as NCG, while 890 patients (33.9%) were belonged to the ICG at 3 month. Within the NCG, 1,460
patients (82.4%) were stable group, 93 patients (5.4%) were converter group, and 212 patients (12.2%) were reverter
group at 12 months onset. Within the ICG group, 472 patients (53.0%) were stable group, 321 patients (36.1%) were
converter group, and 97 patients (10.9%) were reverter group. When different factors were investigated, the three
subgroups in NCG and ICG showed significant different factors affecting cognitive function from 3 to 12 month.
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Conclusions: The prevalence of cognitive impairment showed difference between 3,12 months. To analyze the
cognitive change from 3 month to 12 month, the proportion stable group was dominant in NCG and converter
group was higher in ICG. By investigating the influencing factors from each group, we were able to identify the
predictors including the age factor.
Keywords: Ischemic stroke, Cognition, Inverter, Reverter, Risk factors
Background
Cerebrovascular stroke is considered one of the main
causes of dementia [1–3]. It may decrease quality of life
in addition to causing other neurological deficits [4].
Post-stroke dementia is defined as a presence of dementia
identified at 3 months after an acute stroke [5]. Reasons
for a stroke patient to develop dementia are still insuffi-
ciently understood. It is not always a direct consequence
of cerebrovascular lesions, and, in some cases, post-stroke
dementia has a progressive course, suggesting a degenera-
tive rather than a vascular origin [6, 7]. In previous aut-
opsy series, 10 to 15% of dementias occurring after a
stroke were found to be due to a combination of vascular
and Alzheimer’s disease [8, 9].
Despite consensus that strokes are associated with an
increased risk of post-stroke dementia, the data regard-
ing prevalence at 3 months post-stroke are still conflict-
ing, with reports ranging from 6% to more than 50%
[10–14]. In addition, cognitive function may vary (either
improve or decline) years after a stroke. Snaphaan et al.
reported that post-stroke memory dysfunction varied
from 23 to 55% at 3 months after a stroke, and this de-
clined from 11 to 31% at 1 year after a stroke. Declined
cognitive function may change. A previous cohort study
showed 33% of patients with mild cognitive impairments
diagnosed in the first 6 months after a stroke showed
improvement at 1 year. Several prospective studies have
identified delayed improvement in cognitive function
after strokes using various diagnostic assessment tools
for dementia [15-17].
The pathophysiology of delayed cognitive change after
a stroke is multifactorial, and the prevalence rate of
post-stroke dementia is higher among older patients
[18, 19]. Previous studies have tracked cognitive
changes to identify the factors associated with delayed
improvement or a decline in cognitive function after
stroke. However, no large-scale study has been con-
ducted to investigate the pattern of post-stroke cogni-
tive changes, identify the risk factors, or compare
age-related differences using repeated administration
of the most commonly used screening tool.
Therefore, we conducted a prospective cohort study in
conjunction with the Korean Stroke Cohort for Func-
tioning and Rehabilitation (KOSCO) to identify 1) the
prevalence of delayed cognitive impairment; patients
progress to either converter, stable, or reverter group
after ischemic stroke and 2) clinical and demographic
factors associated with improvement or decline in cogni-
tive function between 3 months and 12 months after is-
chemic stroke. The present study is the first to involve a
large and well-characterized Korean cohort, a battery of
short cognitive and functional assessments, and a 1-year
follow-up.
Methods
Study design
KOSCO is a large, multi-centered, prospective cohort
study of all acute, first-time stroke patients admitted to
participating hospitals in nine distinct areas of Korea. A
written informed consent is obtained from all patients
prior to inclusion in the study, and the study protocols
were approved by the ethics committee of each hospital.
The detailed rationale and protocols of KOSCO were de-
scribed in a previous article [20].
Study subjects
All consecutive patients with an acute, first-time IS
admitted to the representative hospitals were asked to
participate in the study. The inclusion criteria were: 1)
first-time ischemic stroke with corresponding lesion on
a MRI/A scan, 2) age ≥19 years at stroke onset, and 3)
onset of symptoms within 7 days prior to inclusion. Ex-
clusion criteria were: 1) recurrent stroke; 2) hemorrhagic
stroke; 3) traumatic intracerebral hemorrhage; 4) previ-
ously diagnosed dementia or cognitive impairment; 5)
persistent aphasia; and 6) history of systemic diseases
known to involve the central nervous system.
Procedure
All eligible patients were recruited from August 2012 to
April 2015 at the time of stroke evaluation. After provid-
ing a written informed consent, patients were formally
enrolled in the study. If a patient was unable to provide
informed consent, the consent was obtained from the
patient’s legally authorized representative.
Demographic and clinical characteristics
Baseline demographic and clinical characteristics of en-
rolled patients were evaluated at 3 months. A complete
enumeration survey of all patients was performed using
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a review of medical records upon the first admission.
Survey items included demographic data and presence
of cerebrovascular risk factors using standardized, struc-
tured questionnaires. The items were classified accord-
ing to the current guidelines of the American Heart
Association [21]. Comorbidities were assessed using the
Charlson comorbidity index [22]. Initial stroke severity
was recorded at the time of hospital arrival using the
Korean National Institute of Health Stroke Scale (K-
NIHSS) for ischemic strokes [23]. Physical examin-
ation findings and laboratory measures were also re-
corded. The course of the disease during admission
was documented including information on medication
use, treatments such as intravenous or arterial
thrombolysis, and complications. Patients that re-
ceived rehabilitation at 3 months were transferred to
the rehabilitation center to initiate active rehabilita-
tion after acute management at the neuroscience cen-
ter. The remaining patients that did not receive any
rehabilitation treatments were discharged or trans-
ferred to other hospitals instead of being transferred
to the Rehabilitation Medicine Department.
Classification of ischemic stroke; etiology, and
neuroimaging
The etiologies of ischemic strokes were classified accord-
ing to the TOAST criteria [24]. Etiology was determined
based on neuro-imaging, medical history, and use of
medication. MRI scans were reviewed by neuroimaging
specialists in each institute. Ischemic strokes were classi-
fied according to arterial territory and as either lacunar
or territorial.
Cognitive assessment
To identify influencing factors by age, we analyzed the
Korean Mini-Mental State Examination (K-MMSE) at
3 months separately between total patients and patients
older than 65 years. To analyze changes in cognitive
function, all patients were divided into normal cognitive
group (NCG) and impaired cognition group (ICG) by
using standard deviation score after correcting raw
scores by age, sex and education level of the patients
[25]. Patients were again classified according to the
changes in their K-MMSE scores between 3 and
12 months after stroke onset into stable groups (NCG-SG,
ICG-SG) with K-MMSE changes ranging from −2 to +2
points (−2 ≤ △MMSE ≤ +2), converter groups (NCG-CG,
ICG-CG) with increases of K-MMSE more than 3 points
(3 ≤ △MMSE), and reverter groups (NCG-RG, ICG-RG)
with score decreases of K-MMSE more than 3 points
(−3 ≤ △MMSE). Factors affecting cognitive change from
3 months to 12 months including baseline medical record,
stroke and treatment characteristics, and various func-
tional assessments after 3 months were analyzed among
the groups (Fig. 1).
Functional assessment battery
At 3 months after stroke onset, a face-to-face functional
assessment was performed. Assessments included the K-
NIHSS for stroke severity, Functional Independence
Measure (FIM) [26], Korean modified Barthel Index (K-
MBI) [27] for activities of daily living, Fugl-Meyer As-
sessment (FMA) [28] for motor function, Functional
Ambulatory Category (FAC) [29] for mobility and gait,
mRS (modified rankin scale) [30] for general functional
level, Geriatric depression scale-short form (GDS-SF)
[31] for mood, and Euro Quality of Life (EQ)-5D [32]
for quality of life (Table 1).
Statistical analysis
For statistical analysis, we used descriptive statistics for
the demographic and clinical characteristics, initial
stroke features and treatment methods. Nominal and or-
dinal data obtained from a baseline review of medical re-
cords and initial stroke features were compared using
frequency analysis. Scale factors were analyzed using
average analysis. Chi-square test and one-way ANOVA
were used to compare the influencing factors among
groups. Bonferroni correction was done for post-hoc
analysis of ANOVA. Statistical analysis was completed
Fig. 1 Flow diagram of this study
Yoon et al. BMC Neurology  (2017) 17:9 Page 3 of 12
using SPSS for Windows version 21.0 (SPSS Inc., Chicago,
IL). P < 0.05 is considered statistically significant.
Results
A total of 2,625 patients (older patients = 1,431) with
first time ischemic stroke were included in this study.
Among these patients, 1,735 (66.1%) (older patients =
835 (58.4%)) were classified as NCG, while 890 patients
(33.9%) (older patients = 596 (41.6%)) were the ICG at
3 month K-MMSE assessment. Although, percentage of
normal and declined cognitive function was similar for
older patients at 3 months and 12 months, percentage of
normal cognition group was slightly increased and per-
centage of declined cognition groups was decreased in
total patients (Fig. 2). Among NCG, 1,460 (82.4%) (older
patients = 612 (73.3%)) were stable group, 93 patients
(5.4%) (older patients = 79 (9.5%)) were converter group, and
212 patients (12.2%) (older patients = 144(17.2%)) were re-
verter group at 12 months onset. Among ICG, 472 patients
(53.0%) (older patients = 336 (56.4%)) were stable group, 321
patients (36.1%) (older patients = 183(30.7%)) were converter
group, and 97 patients (10.9%) (older patients = 77 (12.9%))
were reverter group (Table 2) (Figs. 3, 4). To analyze the cog-
nitive change from 3 month to 12 month, the proportion
stable group was dominant in NCG and converter group
was higher in ICG.
Among NCG of total patients, hypertension, and cor-
tical or multiple level involvement was dominant in re-
verter group, male sex, lower onset age, higher education
level were dominant in stable group. In addition, func-
tional assessments in stable group including NIHSS, mRS,
FIM, K-MBI, FAC, GDS, and EQ-5D at 3 months were
significantly better in scores compared to other groups.
For the tendency of ICG of total patients, onset age,
hypertension history was higher, education level was lower
in reverter group. All functional assessments at 3 months
showed better scores in converter groups and worse
scores in reverter group (Table 3). Among separated older
patients, male sex, lower onset age were dominant in
stable group, educational level was lower in reverter
group. Functional assessments including NIHSS, mRS,
FIM, K-MBI, FAC, GDS, and EQ-5D, at 3 months showed
better scores in stable group compared to others. In
addition, proportion of receiving rehabilitation therapy at
3 months was lower and all functional l assessments
showed better scores in converter group compared to
others (Table 4).
Table 1 Functional assessments at 3 months
Domain Assessment
Stroke severity National Institute of Health Stroke
Scale (NIHSS)
Activities of daily living Korean modified Barthel Index (K-MBI)
Functional Independence Measure (FIM)
Cognition function Korean Mini-Mental State Examination
(K-MMSE)
Motor function Fugl-Meyer Assessment (FMA)
Modified Ashworth scale (mRS)
Mobility function Functional Ambulatory Category (FAC)
Mood Geriatric depression scale-short form (GDS)
Quality of life Euro Quality of Life-5D
a
b
Fig. 2 Cognitive function of patients at 3 months and 12 months after stroke onset
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Discussion
In our study, total the percentage of cognitive impair-
ment group did not change at 12 months compared to
3 months assessment. Otherwise, the percentage of cog-
nitive impairment at 3 months, the percentage of pa-
tients in the reverter group, and the percentage of
patients transferring from the NCG to the ICG at
12 months were higher in older patients compared to
total group analysis (Table 2) (Fig. 2). Influencing factors
for delayed cognitive change were discretely determined
in the NCG and ICG of total and older patients. Hyper-
tension history and onset age, sex, education level were
somewhat repeated influencing factors. Although pres-
ence of atrial fibrillation, smoking, alcohol history
showed statistical significance, large difference of
number of patients between groups made it difficult to
define it as meaningful result. Another unique aspect of
our study is that we included functional assessment
since it could influence on patients’ delayed cognitive
function. Patients with better functional assessment
scores not only in cognitive field but in all other do-
mains including activities of daily living, motor function,
mobility and gait, general functional level, quality of life
at 3 month tend to have less cognitive decline and more
cognitive improvement from 3 month to 12 month.
Otherwise, stroke characteristics including ischemic
type, location, treatment characteristics showed no sig-
nificant difference between the groups. Patients in the
ICG-RG that were aged >65 years received more re-
habilitation therapy. Moreover, compared to the other
Table 2 Cognitive change divided by age from 3 months to 12 months
Age Group n (%) Cognitive Change 3 months after onset 12 months after onset
n (%) K-MMSE (mean ± SD) K-MMSE (mean ± SD)
Total Subjects
(n = 2,625)
Normal Cognition 1,735
(66.1)
Stable 1,430 (82.4) 28.09 ± 2.66 28.14 ± 2.75
Converter 93 (5.4) 23.67 ± 3.60 27.41 ± 3.19
Reverter 212 (12.2) 26.81 ± 3.53 22.00 ± 4.80
Declined Cognition 890
(33.9)
Stable 472 (53.0) 16.14 ± 9.81 16.42 ± 10.09
Converter 321 (36.1) 17.87 ± 9.81 24.11 ± 5.69
Reverter 97 (10.9) 16.34 ± 7.27 11.03 ± 7.46
Older age
(n = 1,431)
Normal Cognition 835
(58.4)
Stable 612 (73.3) 26.86 ± 3.41 26.88 ± 3.50
Converter 79 (9.5) 23.18 ± 3.69 27.01 ± 3.30
Reverter 144 (17.2) 25.85 ± 3.82 20.66 ± 4.90
Declined Cognition 596
(41.6)
Stable 336 (56.4) 14.46 ± 9.71 14.68 ± 9.95
Converter 183 (30.7) 15.95 ± 7.64 22.46 ± 5.78
Reverter 77 (12.9) 16.08 ± 7.09 10.52 ± 7.21
n, Number; SD, Standard Deviation; K-MMSE, Korean Mini Mental State Examination
a b
Fig. 3 Cognitive change of total patients from 3 months to 12 months
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patient groups, the patients in the ICG-SG received less
cognitive therapy, which was a component of the re-
habilitation therapy. We believe that unlike the other
factors, the administration of rehabilitation treatment
depended on the cognitive status of the patient; however,
rehabilitation was not a factor that improved cognitive
function.
Stroke severity, onset age, pre-stroke cognitive func-
tion, level of education, and bilateral lesions are well-
known factors associated with development of post-
stroke dementia [33–36]. In contrast, a cohort study of
younger stoke patients (mean age, 60 years) showed that
more than 30% of the patients with mild cognitive im-
pairments between 0 and 6 months were classified as
cognitively intact by 12 to 18 months [16]. For older pa-
tients (mean age, 80.4 ± 3.8), about 50% of the patients
experienced an improvement in MMSE at 15 months
[17]. As the prognosis of stroke varies according to the
patient’s age at onset, identifying the factors affecting
cognitive changes by age might aid in both preventing
secondary cognitive decline, and enhancing post-stroke
cognitive function. In our study, separating patients by
age, cognitive function at 3 month, and aspect of cogni-
tive change to find the propensity of each prevalence
and influencing factors was meaningful. Also, compared
to other cross sectional studies, our study analyzed de-
layed post stroke cognitive function and focused on
amount and aspect of cognitive change from 3 month to
12 month and its influencing factors.
To carry this analysis further, we examined the differ-
ences in the MMSE scores among the groups by using
the cutoff score of <24 points, conventionally accepted
for the diagnosis of significant cognitive impairment, i.e.,
dementia [37]. Previous studies have established more
than 3 points of MMSE variability as a significant change
for improvement or decline in cognitive function.
MMSE is the most frequently applied test for dementia
screening. A systematic review and meta-analysis examin-
ing cognitive tests to detect dementia found 10,263 cases
of dementia identified from 36,080 participants in 108 co-
hort studies. The result reported a sensitivity of 0.81 and a
specificity of 0.89 for the MMSE [38]. The MMSE requires
only 5–10 min to evaluate various cognitive domains
(orientation, memory, language, attention, visuospatial)
and is practical to use serially and routinely [39].
The overall prevalence of dementia in subjects aged
greater than 65 in Korea is estimated to be 9.2%. In
addition, the pooled age-specific prevalence of dementia is
estimated to increase with each 5-year age band (65–69
years) [40]. This result is much higher than the estimated
overall prevalence of dementia in Asian people [41]. We
analyzed our data by separating patients older than 65 y/o
to compare the age factors. The percentages of normal
cognitive group and cognitive impaired patients and mean
MMSE scores showed significant differences between total
and older patient groups. In particular, the percentage of
patients in the reverter group was higher and the con-
verter group was lower at 12 months in older patient
group, and their average MMSE showed differences by
age. Otherwise, in older ICG, less factors were significant
compared to other groups. This finding may be due to the
lower percentage of patients when compared to the entire
study population and NCG.
Limitations
First, we only used a MMSE to test cognitive function.
Although there are 40 other more detailed tests for de-
mentia diagnosis in healthcare settings, we required
a b
Fig. 4 Cognitive change of the older patient group from 3 months to 12 months
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Table 3 Factors affecting cognitive change from 3 months to 12 months in total patients
Parameters Normal Cognition (n = 1,735) Declined Cognition (n = 890)
Stable (n = 1,430) Converter (n = 93) Reverter (n = 212) P value Stable (n = 472) Converter (n = 321) Reverter (n = 97) P value
1) Baseline medical record assessments
Male, n (%) 991 (69.3) 46 (49.5) 107 (50.5) .000** 248 (52.5) 185 (57.6) 52 (53.6) .362
Age, (mean ± SD) 61.52 ± 12.53a 69.44 ± 11.16b 73.75 ± 8.85c .000
** 70.32 ± 11.07a 66.34 ± 11.54b 72.32 ± 9.45ab .000
**
Education, n (%)
Uneducated 114 (8.0) 25 (26.9) 44 (20.8) .000** 35 (7.4) 11 (3.4) 13 (13.4) .000**
0–3 years 46 (3.2) 10 (10.8) 12 (5.7) 40 (8.5) 26 (8.1) 11 (11.3)
4–6 years 189 (13.2) 25 (26.9) 52 (24.5) 117 (24.8) 73 (22.7) 27 (27.8)
7–9 years 222 (15.5) 17 (18.3) 45 (21.2) 113 (23.9) 70 (21.8) 21 (21.6)
10–12 years 468 (32.7) 8 (8.6) 36 (17.0) 135 (28.6) 93 (29.0) 19 (19.6)
13 years– 391 (27.3) 8 (8.6) 23 (10.8) 32 (6.8) 48 (15.0) 6 (6.2)
BMI (kg/m2), (mean ± SD) 24.10 ± 3.28a 23.59 ± 3.61ab 23.49 ± 3.33b .023
* 23.35 ± 3.08 23.47 ± 3.30 22.62 ± 3.27 .071
Risk factors of stroke, n (%)
Hypertension 779 (54.5) 63 (67.7) 118 (88.7) .030* 275 (58.3) 178 (55.5) 68 (70.1) .037*
Diabetes Mellitus 206 (14.4) 15 (16.1) 24 (11.3) .412 70 (14.8) 44 (13.7) 22 (22.7) .091
Coronary heart disease 98 (6.9) 9 (9.7) 15 (7.1) .587 40 (8.5) 20 (6.2) 5 (5.2) .339
Atrial fibrillation 118 (8.3) 14 (15.1) 27 (12.7) .014* 68 (14.4) 37 (11.5) 11 (11.3) .433
Hyperlipidemia 246 (17.2) 12 (12.9) 39 (18.4) .493 54 (11.4) 42 (13.1) 15 (15.5) .505
Obesity 190 (13.3) 14 (15.1) 23 (10.8) .522 49 (10.4) 40 (12.5) 4 (4.1) .063
Family history 135 (9.4) 5 (5.4) 20 (9.4) .420 48 (10.2) 26 (8.1) 7 (7.2) .483
Smoking, n (%)
Current smokers 462 (32.3) 17 (18.3) 44 (20.8) .000** 127 (26.9) 87 (27.1) 29 (29.9) .859
Former smokers 202 (14.1) 10 (10.8) 19 (9.0) 55 (11.7) 39 (12.1) 8 (8.2)
Never smokers 766 (53.6) 66 (71.0) 149 (70.3) 290 (61.4) 195 (60.7) 60 (61.9)
Alcohol consumption, n (%)
None 793 (55.5) 62 (66.7) 144 (67.9) .002** 327 (69.3) 202 (63.0) 67 (69.1) .253
Moderate 452 (31.6) 23 (24.7) 42 (19.8) 97 (20.6) 72 (22.4) 21 (21.6)
Heavy 185 (12.9) 8 (8.6) 26 (12.3) 48 (10.2) 47 (14.6) 9 (9.3)
2) Stroke characteristics
Ischemic type (TOAST)
Large–artery atherosclerosis 641 (44.8) 58 (62.4) 101 (47.6) .062 229 (48.5) 173 (53.9) 56 (57.7) .572
Small-artery occlusion 373 (26.1) 14 (15.1) 53 (25.0) 85 (18.0) 57 (17.8) 15 (15.5)
Cardioembolism 156 (10.9) 6 (6.5) 24 (11.3) 74 (15.7) 39 (12.1) 9 (9.3)
Other determined 115 (8.0) 4 (4.3) 12 (5.7) 29 (6.1) 14 (4.4) 5 (5.2)
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Table 3 Factors affecting cognitive change from 3 months to 12 months in total patients (Continued)
Undetermined ischemic stroke 145 (10.1) 11 (11.8) 22 (10.4) 55 (11.7) 38 (11.8) 12 (12.4)
Ischemic location
Rt. hemisphere 680 (47.6) 46 (49.5) 99 (46.7) .580 178 (37.7) 117 (36.4) 41 (42.3) .698
Lt. hemisphere 648 (45.3) 37 (39.8) 94 (44.3) 262 (55.5) 185 (57.6) 48 (49.5)
Both hemisphere 102 (7.1) 10 (10.8) 19 (9.0) 178 (37.7) 19 (5.9) 8 (8.2)
Affected level
Cortical level 440 (30.8) 37 (39.8) 70 (33.0) .007** 191 (40.5) 139 (43.3) 41 (42.3) .878
Subcortical level 454 (31.7) 22 (23.7) 49 (23.1) 115 (24.4) 83 (25.9) 25 (25.8)
Brainstem level 330 (23.1) 13 (14.0) 58 (27.4) 63 (13.3) 41 (12.8) 14 (14.4)
Multiple level 206 (14.4) 21 (22.6) 35 (16.5) 103 (21.8) 58 (18.1) 17 (17.5)
3) Treatment characteristics
IV thrombolysis 104 (7.3) 7 (7.5) 13 (6.1) .826 43 (9.1) 29 (9.0) 15 (15.5) .136
IA thrombolysis 21 (1.5) 3 (3.2) 4 (1.9) .404 23 (4.9) 9 (2.8) 2 (2.1) .208
IV heparin 121 (8.5) 5 (5.4) 17 (8.0) .573 33 (7.0) 18 (5.6) 10 (10.3) .271
Antiplatelet agent 1,140 (79.7) 77 (82.8) 166 (78.3) .668 333 (70.6) 240 (74.8) 65 (67.0) .241
Rehabilitation Therapy 386 (27.0) 29 (31.2) 59 (27.8) .669 187 (60.4) 116 (36.1) 43 (44.3) .311
Cognitive Therapy 56 (3.9) 4 (4.3) 9 (4.2) .961 28 (5.9) 33 (10.3) 11 (11.3) .041*
4) Functional assessments
Cognitive function (K-MMSE)
3 months from onset 28.09 ± 2.66a 23.67 ± 3.60b 26.81 ± 3.53c .000
** 16.14 ± 9.81a 17.87 ± 7.81b 16.34 ± 7.27ab .024
*
12 months from onset 28.14 ± 2.75a 27.41 ± 3.19a 22.00 ± 4.80b .000
** 16.42 ± 10.09a 24.11 ± 5.69b 11.03 ± 7.46c .000
**
Variation (from 3 months to 12 months) 0.05 ± 1.07a 3.41 ± 1.23b −4.81 ± 2.91c .000
** 0.29 ± 1.09a 6.25 ± 4.19b −5.31 ± 2.81c .000
**
Stroke Severity, ADL, Motor, Gait,
Depression, QoL (3 months from onset)
NIHSS 0.77 ± 1.85a 1.11 ± 2.03ab 1.12 ± 2.02b .015
* 5.09 ± 6.86a 3.12 ± 4.62b 5.25 ± 4.63a .000
**
mRS 0.99 ± 1.02a 1.44 ± 1.28b 1.43 ± 1.20b .000
** 2.57 ± 1.68a 2.17 ± 1.52b 3.15 ± 1.29c .000
**
FIM 120.00 ± 12.73a 114.16 ± 17.39b 113.93 ± 18.05b .000
** 88.70 ± 38.13a 100.18 ± 30.85b 82.80 ± 30.61a .000
**
K-MBI 95.44 ± 11.90a 90.03 ± 16.88b 89.88 ± 17.34b .000
** 69.11 ± 36.99a 79.71 ± 28.65b 63.41 ± 30.94a .000
**
FMA 94.11 ± 15.80 91.19 ± 18.70 89.88 ± 17.34 .119 72.75 ± 35.71a 81.68 ± 30.77b 63.65 ± 35.07c .000
**
FAC 4.66 ± 0.87a 6.59 ± 4.07b 6.74 ± 4.40b .000
** 3.10 ± 2.03a 3.65 ± 1.77b 2.66 ± 1.83a .000
**
GDS 4.95 ± 3.79a 6.59 ± 4.07b 6.74 ± 4.40b .000
** 7.25 ± 4.11a 7.30 ± 4.32a 9.31 ± 3.92b .006
**
EQ-5D 0.78 ± 0.28a 0.69 ± 0.33b 0.65 ± 0.36b .000
** 0.44 ± 0.41a 0.53 ± 0.40b 0.31 ± 0.37c .000
**
n, Number; SD, Standard Deviation; BMI, Body Mass Index; TOAST, Trial of Org 10172 in Acute Stroke Treatment; Rt, Right; Lt, Left; IV, Intra-Venous; IA, Intra-Artrial; K-MMSE, Korean Mini Mental State Examination; NIHSS,
National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; ADL, Activity of Daily Living; FIM, Functional Independence Measure; K-MBI, Korean version of Modified Barthel Index; FMA, Fugl-Meyer Assessment;
FAC, Functional Ambulation Categories; GDS, Geriatric Depression Scale; QoL, Quality of Life; EQ-5D, EuroQol-5D
* p < 0.05; ** p < 0.01
abc Post HOC group
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Table 4 Factors affecting cognitive change from 3 months to 12 months in older patients
Parameters Normal Cognition (n = 835) Declined Cognition (n = 596)
Stable (n = 612) Converter (n = 79) Reverter (n = 144) P value Stable (n = 336) Converter (n = 183) Reverter (n = 77) P value
1) Baseline medical record assessments
Male, n (%) 375 (61.3) 37 (46.8) 66 (45.8) .000** 163 (48.5) 91 (49.7) 38 (49.4) .963
Age, (mean ± SD) 73.15 ± 5.86a 75.24 ± 6.84b 76.53 ± 6.21b .000
** 76.06 ± 6.15 74.78 ± 5.55 75.95 ± 6.09 .059
Education, n (%)
Uneducated 98 (16.0) 24 (30.4) 41 (28.5) .000** 33 (9.8) 10 (5.5) 12 (15.6) .307
0–3 years 34 (5.6) 9 (11.4) 10 (6.9) 36 (10.7) 20 (10.9) 9 (11.7)
4–6 years 132 (21.6) 22 (27.8) 43 (29.9) 106 (31.5) 61 (33.3) 23 (29.9)
7 - 9 years 103 (16.8) 12 (15.2) 25 (17.4) 74 (22.0) 35 (19.1) 17 (22.1)
10 - 12 years 142 (23.2) 4 (5.1) 15 (10.4) 71 (21.1) 41 (22.4) 13 (16.9)
13 years - 103 (16.8) 8 (10.1) 10 (6.9) 16 (4.8) 16 (8.7) 3 (3.9)
BMI (kg/m2), (mean ± SD) 23.72 ± 3.20 23.59 ± 3.61 23.11 ± 3.43 .115 23.00 ± 2.96 23.24 ± 3.15 22.26 ± 3.23 .066
Risk factors of stroke, n (%)
Hypertension 414 (67.6) 54 (68.4) 91 (63.2) .570 212 (63.1) 116 (63.4) 55 (71.4) .371
Diabetes Mellitus 102 (16.7) 12 (15.2) 15 (10.4) .175 55 (16.4) 28 (15.3) 17 (22.1) .392
Coronary heart disease 60 (9.8) 8 (10.1) 11 (7.6) .711 27 (8.0) 16 (8.7) 5 (6.5) .831
Atrial fibrillation 78 (12.7) 11 (13.9) 22 (15.3) .712 59 (17.6) 27 (14.8) 10 (13.0) .515
Hyperlipidemia 110 (18.0) 11 (13.9) 31 (21.5) .357 39 (11.6) 19 (10.4) 12 (15.6) .489
Obesity 79 (12.9) 12 (15.2) 11 (7.6) .154 29 (8.6) 20 (10.9) 3 (3.9) .185
Family history 52 (8.5) 4 (5.1) 11 (7.6) .562 30 (8.9) 12 (6.6) 6 (7.8) .635
Smoking, n (%)
Current smokers 105 (17.2) 11 (13.9) 23 (16.0) .050 67 (19.9) 27 (14.8) 19 (24.7) .285
Former smokers 107 (17.4) 10 (12.7) 12 (8.3) 39 (11.6) 28 (15.3) 8 (10.4)
Never smokers 400 (65.4) 58 (73.4) 109 (75.7) 230 (68.5) 128 (69.9) 50 (64.9)
Alcohol consumption, n (%)
None 414 (67.6) 54 (68.4) 108 (75.0) .322 249 (74.1) 133 (72.7) 56 (72.7) .367
Moderate 141 (23.0) 20 (25.3) 23 (16.0) 63 (18.8) 28 (15.3) 15 (19.5)
Heavy 57 (9.3) 5 (6.3) 13 (9.0) 24 (7.1) 22 (12.0) 6 (7.8)
2) Stroke characteristics
Ischemic type (TOAST)
Large-artery atherosclerosis 278 (45.4) 51 (64.6) 67 (46.5) .052 167 (49.7) 94 (51.4) 46 (59.7) .662
Small-artery occlusion 155 (25.3) 11 (13.9) 39 (27.1) 60 (17.9) 34 (18.6) 12 (15.6)
Cardioembolism 89 (14.5) 5 (6.3) 17 (11.8) 59 (17.6) 28 (15.3) 7 (9.1)
Other determined 36 (5.9) 4 (5.1) 5 (3.5) 15 (4.5) 5 (2.7) 4 (5.2)
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Table 4 Factors affecting cognitive change from 3 months to 12 months in older patients (Continued)
Undetermined ischemic stroke 54 (8.8) 8 (10.1) 16 (11.1) 35 (10.4) 22 (12.0) 8 (10.4)
Ischemic location
Rt. hemisphere 309 (50.5) 39 (49.4) 64 (44.4) .394 135 (40.2) 68 (37.2) 33 (42.9) .667
Lt. hemisphere 247 (40.4) 31 (39.2) 70 (48.6) 178 (53.0) 106 (57.9) 38 (49.4)
Both hemisphere 56 (9.2) 9 (11.4) 10 (6.9) 23 (6.8) 9 (4.9) 6 (7.8)
Affected level
Cortical level 203 (33.2) 32 (40.5) 49 (34.0) .047* 143 (42.6) 75 (41.0) 32 (41.6) .729
Subcortical level 193 (31.5) 20 (25.3) 30 (20.8) 83 (24.7) 53 (29.0) 21 (27.3)
Brainstem level 125 (20.4) 11 (13.9) 40 (27.8) 42 (12.5) 20 (10.9) 13 (16.9)
Multiple level 91 (14.9) 16 (20.3) 25 (17.4) 68 (20.2) 35 (19.1) 11 (14.3)
3) Treatment characteristics
IV thrombolysis 40 (6.5) 5 (6.3) 9 (6.3) .991 27 (8.0) 16 (8.7) 7 (9.1) .935
IA thrombolysis 9 (1.5) 2 (2.5) 3 (2.1) .722 20 (6.0) 4 (2.2) 1 (1.3) .049*
IV heparin 52 (8.5) 5 (6.3) 9 (6.3) .575 29 (8.6) 10 (5.5) 8 (10.4) .301
Antiplatelet agent 485 (79.2) 65 (82.3) 115 (79.9) .818 239 (71.1) 131 (71.6) 53 (68.8) .901
Rehabilitation Therapy 157 (25.7) 25 (31.6) 43 (29.9) .363 133 (39.6) 54 (29.5) 36 (46.8) .015*
Cognitive Therapy 26 (4.2) 4 (5.1) 5 (3.5) .844 19 (5.7) 11 (6.0) 10 (13.0) .061
4) Neuropsychological assessments
Cognitive function (K-MMSE)
3 months from onset 26.86 ± 3.41a 23.18 ± 3.69b 25.85 ± 3.82c .000
** 14.46 ± 9.71 15.95 ± 7.64 16.08 ± 7.09 .112
12 months from onset 26.88 ± 3.50a 27.01 ± 3.30a 20.66 ± 4.90b .000
** 14.68 ± 9.95a 22.46 ± 5.78b 10.52 ± 7.21c .000
**
Variation (from 3 months to 12 months) 0.03 ± 1.17a 3.84 ± 1.31b −5.19 ± 3.05c .000
** 0.21 ± 1.10a 6.51 ± 4.03b −5.56 ± 2.99c .000
**
Stroke Severity, ADL, Motor, Gait, Depression, QoL (3 months from onset)
NIHSS 0.78 ± 1.98a 1.15 ± 2.06a 1.32 ± 2.15b .009
** 5.75 ± 7.43a 3.17 ± 4.69b 5.08 ± 4.68b .000
**
mRS 1.12 ± 1.12a 1.51 ± 1.32b 1.63 ± 1.25b .000
** 2.79 ± 1.68a 2.37 ± 1.54b 3.26 ± 1.29a .000
**
FIM 117.40 ± 15.58a 113.08 ± 18.30ab 111.16 ± 19.83b .000
** 83.68 ± 39.78a 95.74 ± 32.33b 81.34 ± 31.60a .001
**
K-MBI 93.31 ± 16.11a 89.09 ± 17.82ab 87.34 ± 19.10b .000
** 64.13 ± 38.83a 75.71 ± 30.51b 61.61 ± 32.50a .001
**
FMA (affected side) 93.92 ± 16.11 90.53 ± 19.31 91.44 ± 17.83 .094 70.49 ± 36.80a 81.45 ± 30.54b 65.90 ± 35.97a .000
**
FAC 4.51 ± 1.05a 4.15 ± 1.40b 4.00 ± 1.35b .000
** 2.83 ± 2.10a 3.45 ± 1.79b 2.70 ± 1.87a .001
**
GDS 5.40 ± 3.79a 6.83 ± 4.19b 7.41 ± 4.35b .000
** 7.63 ± 4.09a 8.03 ± 4.27ab 9.65 ± 4.04b .022
*
EQ-5D 0.76 ± 0.29a 0.67 ± 0.34b 0.63 ± 0.36b .000
** 0.39 ± 0.41a 0.49 ± 0.40b 0.31 ± 0.37a .003
**
n, Number; SD, Standard Deviation; BMI, Body Mass Index; TOAST, Trial of Org 10172 in Acute Stroke Treatment; Rt, Right; Lt, Left; IV, Intra-Venous; IA, Intra-Artrial; K-MMSE, Korean Mini Mental State Examination; NIHSS,
National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; ADL, Activity of Daily Living; FIM, Functional Independence Measure; K-MBI, Korean version of Modified Barthel Index; FMA, Fugl-Meyer Assessment;
FAC, Functional Ambulation Categories; GDS, Geriatric Depression Scale; QoL, Quality of Life; EQ-5D, EuroQol-5D
* p < 0.05; ** p < 0.01
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multi-domain, serial functional assessments for screen-
ing and detecting post stroke cognitive decline. Also,
MMSE was optimal for our insurance benefits and med-
ical policy which can be done consecutively for our
large-scale cohort study [40].
Second, we excluded patients with pre-stroke cognitive
decline, but we had no objective assessment data on
which to base our exclusions. Instead, patients’ pre-stroke
cognitive function was determined by administered ques-
tionnaires and face-to-face interviews. Additional studies,
such as volumetric analysis by MRI/MRA scans, may be
valuable to investigate and compare the severity of stroke
among the groups.
Third, we excluded patients who are not capable of
1 year follow up examination including functional as-
sessments which could make selection bias. However, it
could be a strength of this cohort study which differs
from others and it may suggest more objective data for
stroke survivors.
Conclusions
The prevalence of cognitive impairment at 3 month
showed difference between total and older patient
groups. To analyze the cognitive change from 3 month
to 12 month, the proportion stable group was dominant
in NCG and converter group was higher in ICG. By in-
vestigating the influencing factors from each group, we
were able to identify the early predictors including the
age factor.
Abbreviations
CG: Converter group; EQ-5D: Euro quality of Life; FAC: Functional ambulatory
category; FIM: Functional independence measure; FMA: Fugl-meyer
assessment; GDS-SF: Geriatric depression scale-short form; ICG: Impaired
cognitive group; K-MBI: Korean modified Barthel index; K-MMSE: Korean mini-
mental State examination; K-NIHSS: Korean national institute of health stroke
scale; KOSCO: Korean stroke cohort for functioning and rehabilitation;
mRS: Modified rankin scale; NCG: Normal cognitive group; RG: Reverter
group; SG: Stable group
Funding
This study was supported by the research program funded by the Korea
Centers for Disease Control and Prevention (2013-2013E3301702).
Availability of data and materials
The datasets analyzed during the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
JAY, YIS, KPP, MSP: contribution to conception and design; acquisition of
data; involvement in drafting the manuscript; final approval of the version to
be published. MKS, JL, DYK, SGL, YIS, GJO, KHN, WHC: contribution to
conception and design; acquisition of data; final approval of the version to
be published. YSL, MCJ, EYH, JHH: acquisition of data; final approval of the
version to be published. YHK: contribution to conception and design;
acquisition of data; revising the manuscript critically; final approval of the
version to be published. All authors read and approved the final manuscript.
Competing interest
The authors declare that they have no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of the Pusan
National University Yangsan Hospital and all patients provided written
informed consent.
Author details
1Department of Rehabilitation Medicine, Pusan National University School of
Medicine, Research Institute of Convergence for Biomedical Science and
Technology, 20, Geumo-ro, Mulgeum, Yangsan 626-770, South Korea.
2Department and Research Institute of Rehabilitation Medicine, Yonsei
University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul
120-752, Republic of Korea. 3Department of Rehabilitation Medicine, School
of Medicine, Chungnam National University, 282 Munhwa-ro, Jung-gu,
Daejeon 301-721, Republic of Korea. 4Department of Rehabilitation Medicine,
Konkuk University School of Medicine, 120-1 Neungdong-ro, Hwayang-dong,
Gwangjin-gu, Seoul 143-729, Republic of Korea. 5Department of Physical and
Rehabilitation Medicine, Chonnam National University Medical School, 42
Jebong-ro, Donggu, Gwangju 501-757, Republic of Korea. 6Department of
Rehabilitation Medicine, Kyung-pook National University College of Medicine,
130 Dongdeok-ro, Jung-gu, Daegu 700-721, Republic of Korea. 7Department
of Rehabilitation Medicine, Jeju University Hospital, University of Jeju College
of Medicine, 15 Aran 13-gil, Jeju 690-767, Republic of Korea. 8Department of
Rehabilitation Medicine, Wonkwang University School of Medicine, 895
Muwang-ro, Iksan, Jeonlabuk-do 570-711, Republic of Korea. 9Research And
Statistical Support, Research Institute of Convergence for Biomedical Science
and Technology, Pusan National University Yangsan Hospital, 20, Geumo-ro,
Mulgeum-eu, Yangsan 626-770, South Korea. 10Department of Neurology,
Pusan National University College of Medicine, Pusan National University
Yangsan Hospital, 20, Geumo-ro, Mulgeum-eu, Yangsan 626-770, South
Korea. 11Department of Physical and Rehabilitation Medicine, Center for
Prevention and Rehabilitation, Heart Vascular and Stroke Institute, Samsung
Medical Center, Sungkyunkwan University School of Medicine, 50
Ilwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea. 12Department
of Rehabilitation Medicine, Pusan National University School of Medicine,
Research Institute for Convergence of Biomedical Science and Technology,
Pusan National University Yangsan Hospital, 20, Geumo-ro, Mulgeum,
Yangsan 626-770, South Korea.
Received: 21 June 2016 Accepted: 7 December 2016
References
1. Hebert R, Brayne C. Epidemiology of vascular dementia.
Neuroepidemiology. 1995;14:240–57.
2. Leys D, Pasquier F, Parnetti L. Epidemiology of vascular dementia.
Haemostasis. 1998;28:134–50.
3. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based
study of dementia in 85-year-olds. N Engl J Med. 1993;328:153–8.
4. de Haan R, Limburg M, Van der Meulen J, Jacobs H, et al. Quality of life after
stroke impact of stroke type and lesion location. Stroke. 1995;26:402–8.
5. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, et al. Clinical
determinants of poststroke dementia. Stroke. 1998;29:75–81.
6. Tatemichi TK, Foulkes MA, Mohr JP, Hewitt JR, Hier DB, Price TR, Wolf
PA. Dementia in stroke survivors in the stroke data bank cohort:
prevalence, incidence, risk factors, and computed tomographic findings.
Stroke. 1990;21:858–66.
7. He’non H, Pasquier F, Durieu I, Godefroy O, Lucas C, Lebert F, Leys D.
Preexisting dementia in stroke patients: baseline frequency, associated
factors, and outcome. Stroke. 1997;28:2429–36.
8. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented
old people. J Neurol Sci. 1970;11:205–42.
9. Katzman R. Vascular disease and dementia. In: Yahr MD, editor. H. Houston
Merritt memorial volume. New York: Raven; 1983. p. 153–76.
10. Madureira S, Guerreiro M, Ferro JM. Dementia and cognitive impairment
three months after stroke. Eur J Neurol. 2001;8:621–27.
11. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke
dementia: incidence and relationship to prestrike cognitive decline.
Neurology. 2001;57:1216–22.
Yoon et al. BMC Neurology  (2017) 17:9 Page 11 of 12
12. Inzitari D, Di Carlo A, Pracucci G, Lamassa M, Vanni P, Romanelli M, et al.
Incidence and determinants of poststroke dementia as defined by an
informant interview method in a hospital-based stroke registry. Stroke. 1998;
29:2087-93.
13. Henon H, Pasquier F, Leys D. Poststroke dementia. Cerebrovasc Dis.
2006;22:61–70.
14. Snaphaan L, de Leeuw FE. Poststroke memory function in nondemented
patients: a systematic review on frequency and neuroimaging correlates.
Stroke. 2007;38:198–203.
15. Desmond DW, Moroney JT, Sano M, Stern Y. Recovery of cognitive function
after stroke. Stroke. 1996;27:1798–803.
16. Tham W, Auchus AP, Thong M, Goh M-L, Chang H-M, Wong M-C, Chen C.
Progression of cognitive impairment after stroke: one year results from
a longitudinal study of Singaporean stroke patients. J Neurol Sci. 2002;
203–204:49–52.
17. Ballard C, Rowan E, Stephens S, Kalaria R, Kenny RA. Prospective follow-up
study between 3 and 15 months after stroke improvements and decline in
cognitive function among dementia-free stroke survivors >75 years of Age.
Stroke. 2003;34:2440–5.
18. Lowery K, Ballard C, Rodgers H, McLaren A, O’Brien J, Rowan E, Stephens S.
Cognitive decline in a prospectively studied group of stroke survivors, with
a particular emphasis on the 75’s. Age Ageing. 2002;31 suppl 3:24–7.
19. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Clinical determinants of
post-stroke dementia in the Helsinki stroke aging memory study (SAM)
cohort. Stroke. 1997;28:785–92.
20. Chang WH, Sohn MK, Lee J, et al. Korean stroke cohort for functioning and
rehabilitation (KOSCO): study rationale and protocol of a multi-centre
prospective cohort study. BMC Neurol. 2015;15:42.
21. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al.
Primary prevention of ischemic stroke. Stroke. 2006;37:1583–633.
22. Bernardini J, Callen S, Fried L, Piraino B. Inter-rater reliability and annual
rescoring of the Charlson comorbidity index. Adv Perit Dial. 2004;20:125–7.
23. Oh MS, Yu KH, Lee JH, Jung S, Ko IS, Shin JH, et al. Validity and reliability of
a Korean version of the national institutes of health stroke scale. J Clin
Neurol. 2012;8:177–83.
24. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG.
Classification of stroke subtypes. Cerebrovasc Dis. 2009;27:493–501.
25. Kang Y, Na DL, Hahn S. A validity study on the Korean mini-mental
state examination (K-MMSE) in dementia patients. J Korean Neurol
Assoc. 1997;15:300–8.
26. Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional
independence measurement and its performance among rehabilitation
inpatients. Arch Phys Med Rehabil. 1993;74:531–6.
27. Jung HY, Park BK, Shin HS, Kang YK, Pyun SB, Paik NJ, et al. Development of
the Korean version of modified barthel index (K-MBI): multi-center study for
subjects with stroke. J Korean Acad Rehabil Med. 2007;31:283–97.
28. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke
hemiplegic patient. 1. A method for evaluation of physical performance.
Scand J Rehabil Med. 1975;7:13–31.
29. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait
assessment in the neurologically impaired. Reliability and meaningfulness
Phys Ther. 1984;64:35–40.
30. Burn JP. Reliability of the modified Rankin scale. Stroke. 1992;23:438.
31. Lesher EL, Berryhill JS. Validation of the geriatric depression scale–short form
among inpatients. J Clin Psychol. 1994;50:256–60.
32. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the
EQ-5D with time trade off for the German population. Eur J Health Econ.
2005;6:124–30.
33. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associatted
with pre-stroke and poststroke dementia: a systematic review and meta-
analysis. Lancet Neurol 2009;8(11):1006–18.
34. Inzitari D, Di Carlo A, Pracucci G, Lamassa M, Vanni P, Romanelli M, Spolveri
S, Adriani P, Meucci I, Landini G, Ghetti A. Incidence and determinants of
poststroke dementia as defined by an informant interview method in a
hospital-based stroke registry. Stroke. 1998;29:2087–93.
35. Desmond DW, Moroney JT, Paik MC. Frequency and clinical determinants of
dementia after ischemic stroke. Neurology. 2000;54:1124–31.
36. Barba R, Martinez ES, Rodriguez GE, Pondal M, Vivancos J, Del Ser T.
Poststroke dementia: clinical features and risk factors. Stroke. 2000;31:
1494–501.
37. Tatemichi TK, Desmond DW, Paik M, et al. The mini-mental state
examination as a screen for dementia following stroke [abstract]. J Clin Exp
Neuropsychol. 1991;13:419.
38. Tsoi K, Chan J, Hirai H, Wong S, Kwok T. Cognitive tests to detect dementia
a systematic review and meta-analysis. JAMA Intern Med. 2015;175:1450–8.
39. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method
for grading the cognitive state of patients for the clinician. J Psychiatr Res.
1975;12:189–98.
40. Kim YJ, Han JW, So YS, Seo JY, Kim KY, Kim KW. Prevalence and trends of
dementia in Korea: a systematic review and meta-analysis. J Korean Med Sci.
2014;29:903–12.
41. Alzheimer’s Disease International. World Alzheimer’s report 2009. London:
Alzheimer’s Disease International, 2009. p. 26.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yoon et al. BMC Neurology  (2017) 17:9 Page 12 of 12
